Neochem Bio Solutions, a veteran in textile specialty chemicals, is set to launch its SME IPO from December 2-4, 2025, aiming to raise ₹45 crore at ₹98 per share, valuing the company at ₹170 crore. Proceeds are primarily earmarked for working capital and debt reduction. While revenue has shown impressive growth from ₹48 crore to ₹84 crore, with profits also rising, a closer inspection reveals some wrinkles. Ballooning trade receivables and a high pre-IPO debt-to-equity ratio of 2:1 point to potential liquidity challenges, with cash flow struggling under significant interest expenses. The estimated P/E of 23-27 seems a bit stretched compared to some peers, suggesting a premium valuation. While Neochem's deep industry roots and experienced team offer a robust foundation for the future, immediate listing gains appear muted, with GMP signals being flat. Investors should tread carefully, conducting thorough personal due diligence. Opinion: This IPO presents a nuanced picture. Neochem's established market presence and growth offer long-term potential. However, the current valuation appears steep, and immediate cash flow concerns, coupled with a high debt load, suggest limited upside for short-term investors. Prudence and a long-term horizon are essential.

#WatchOutFor#TechnicalViews#FundamentalViews#IPO#Miscellaneous

998 likes·78 comments